OMNIPAQUE (GE Healthcare Inc.)


Welcome to the PulseAid listing for the OMNIPAQUE drug offered from GE Healthcare Inc.. This Radiographic Contrast Agent [EPC],X-Ray Contrast Activity [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: GE Healthcare Inc.
NON-PROPRIETARY NAME: Iohexol
SUBSTANCE NAME: IOHEXOL
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Radiographic Contrast Agent [EPC],X-Ray Contrast Activity [MoA]
ROUTE: INTRAVASCULAR; INTRAVENOUS; ORAL
DOSAGE FORM: INJECTION
MARKETING CATEGORY NAME: NDA
START MARKETING DATE: 2006-07-21
END MARKETING DATE: 0000-00-00


OMNIPAQUE HUMAN PRESCRIPTION DRUG Details:

Item DescriptionOMNIPAQUE from GE Healthcare Inc.
LABELER NAME: GE Healthcare Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 755(mg/mL)
START MARKETING DATE: 2006-07-21
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0407-1414_8189551d-c91e-4031-88d9-3dd0f2ab8c97
PRODUCT NDC: 0407-1414
APPLICATION NUMBER: NDA018956

Other IOHEXOL Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
GE HealthcareOmnipaque
GE Healthcare Inc.OMNIPAQUE
Interpharma Praha, a.s.ORALTAG